Artelo Biosciences Files 8-K
Ticker: ARTL · Form: 8-K · Filed: Sep 15, 2025 · CIK: 1621221
Sentiment: neutral
Topics: 8-K, filing, corporate-update
Related Tickers: ARTL
TL;DR
ARTL filed an 8-K on 9/15 for an event on 9/11. Details on exhibits and other events.
AI Summary
Artelo Biosciences, Inc. filed an 8-K on September 15, 2025, reporting an event that occurred on September 11, 2025. The filing pertains to 'Other Events' and includes 'Financial Statements and Exhibits'. The company, formerly known as Reactive Medical Inc. and Knight Knox Development Corp., is incorporated in Nevada and headquartered in Solana Beach, California.
Why It Matters
This 8-K filing indicates a material event or update for Artelo Biosciences, Inc., requiring disclosure to investors and the public.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for 'Other Events' and does not appear to disclose any immediate negative financial or operational news.
Key Players & Entities
- ARTELO BIOSCIENCES, INC. (company) — Filer
- September 11, 2025 (date) — Earliest event reported
- September 15, 2025 (date) — Date of report
- REACTIVE MEDICAL INC. (company) — Former company name
- KNIGHT KNOX DEVELOPMENT CORP. (company) — Former company name
- Nevada (jurisdiction) — State of incorporation
- Solana Beach, CA (location) — Principal executive offices
- 858-925-7049 (phone_number) — Business phone
FAQ
What specific 'Other Events' are detailed in this 8-K filing?
The filing indicates 'Other Events' as an item, but the specific details of these events are not provided in the provided text excerpt. Further review of the full filing document would be necessary.
What is the significance of filing 'Financial Statements and Exhibits'?
Filing 'Financial Statements and Exhibits' suggests that the company is providing updated financial information or supplementary documents that are material to investors.
When did Artelo Biosciences, Inc. change its name from Reactive Medical Inc.?
The filing states the date of name change from Reactive Medical Inc. was February 7, 2017.
What is Artelo Biosciences, Inc.'s state of incorporation and fiscal year end?
Artelo Biosciences, Inc. is incorporated in Nevada and its fiscal year ends on December 31.
What is the SEC file number and film number for this filing?
The SEC file number is 001-38951 and the film number is 251314499.
Filing Stats: 629 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2025-09-15 16:15:31
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ARTL The Nasdaq Stock Mar
- $4.40 — on Stock"), at a price to the public of $4.40 per share (the "Share Purchase Price"),
- $4.399 — curities"), at a price to the public of $4.399 per Pre-funded Warrant, for aggregate g
- $3,000,000, b — gregate gross proceeds of approximately $3,000,000, before deducting underwriting discounts a
- $0.25 million — roceeds to the Company of approximately $0.25 million and net proceeds of approximately $0.24
- $0.24 million — llion and net proceeds of approximately $0.24 million. The closing of this exercise of the Ov
Filing Documents
- artl_8k.htm (8-K) — 27KB
- 0001640334-25-001680.txt ( ) — 141KB
- artl-20250911.xsd (EX-101.SCH) — 5KB
- artl-20250911_lab.xml (EX-101.LAB) — 15KB
- artl-20250911_cal.xml (EX-101.CAL) — 1KB
- artl-20250911_pre.xml (EX-101.PRE) — 9KB
- artl-20250911_def.xml (EX-101.DEF) — 2KB
- artl_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. As previously disclosed, on September 4, 2025, Artelo Biosciences, Inc. (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with R. F. Lafferty & Co., Inc., the sole book-running manager and underwriter (the "Underwriter"), relating to an underwritten offering (the "Offering") of (i) 640,924 shares (the "Shares") of common stock, par value $0.001 per share, of the Company (the "Common Stock"), at a price to the public of $4.40 per share (the "Share Purchase Price"), and (ii) pre-funded warrants to purchase up to 40,894 shares of Common Stock at an exercise price of $0.001 per share (the "Pre-funded Warrants," and, together with the Shares, the "Securities"), at a price to the public of $4.399 per Pre-funded Warrant, for aggregate gross proceeds of approximately $3,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. The Offering was closed on September 5, 2025. The Company delivered the Securities to the Underwriter on the same day. Pursuant to the Underwriting Agreement, the Company granted the Underwriter a 45-day option (the "Over-allotment Option") to purchase up to an additional 102,272 shares of Common Stock at the Share Purchase Price per share, less the underwriting discounts to cover over-allotments, if any. On September 11, 2025, the Underwriter exercised the Over-allotment Option in part to purchase an additional 57,914 shares of Common Stock, generating gross proceeds to the Company of approximately $0.25 million and net proceeds of approximately $0.24 million. The closing of this exercise of the Over-allotment Option took place on the same day.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 15, 2025 ARTELO BIOSCIENCES, INC. /s/ Gregory D. Gorgas Name: Gregory D. Gorgas Title: Chief Executive Officer and President 3